• Side Effects of Disitamab Vedotin for Injection

  Disitamab Vedotin for Injection is a targeted anticancer agent, mainly used for the treatment of advanced solid tumors with HER2 expression. Common si···【Read More】

  Update: 2026-02-10Source: Haiou HealthViews: 77

• Dosage Standard for Disitamab Vedotin

  The recommended dose of Disitamab Vedotin is generally 2.5 mg/kg every 2 weeks, administered via intravenous infusion. The specific dosage should be a···【Read More】

  Update: 2026-02-10Source: Haiou HealthViews: 80

• Disitamab Vedotin Prescribing Information

  Disitamab vedotin is a novel targeted therapeutic agent whose active ingredient is anti-HER2 antibody. It acts by disrupting the internal structural s···【Read More】

  Update: 2026-02-09Source: Haiou HealthViews: 81

• What Foods to Avoid When Taking Fluzoparib Capsules

  When taking Fluzoparib Capsules, you must avoid grapefruit and any foods or beverages containing grapefruit ingredients. You should also reduce intake···【Read More】

  Update: 2026-02-06Source: Haiou HealthViews: 74

• Important Usage Information for Fluzoparib Capsules

  Fluzoparib Capsules are a type of PARP (Poly(ADP-ribose) polymerase) inhibitor, primarily indicated for the treatment of malignant tumors such as spec···【Read More】

  Update: 2026-02-06Source: Haiou HealthViews: 77

• Adverse Reactions of Fluzoparib Capsules

  Fluzoparib Capsules is a PARP inhibitor primarily indicated for the treatment of specific types of malignant tumors including ovarian cancer and breas···【Read More】

  Update: 2026-02-06Source: Haiou HealthViews: 75

• Fluzoparib Capsules: Dosage and Administration

  The usual dosage of fluzoparib capsules is 150 mg (1 capsule) twice daily, which may be taken on an empty stomach or with meals. The specific dosage s···【Read More】

  Update: 2026-02-06Source: Haiou HealthViews: 82

• Fluzoparib Capsules Package Insert Capsules Package Insert

  The active ingredient of fluzoparib is fluzoparib, a PARP inhibitor targeted anticancer drug. It exerts its anticancer effect by inhibiting the DNA re···【Read More】

  Update: 2026-02-06Source: Haiou HealthViews: 75

• Is Golidocitinib a Chemotherapeutic Agent or a Targeted Therapy Drug?

  Golidocitinib is a targeted therapy drug classified as a Janus kinase (JAK) signaling pathway inhibitor. It exerts its therapeutic effect by specifica···【Read More】

  Update: 2026-02-05Source: Haiou HealthViews: 75

• How Long Can Golidocitinib Be Taken Continuously?

  The duration of golidocitinib administration is determined by a comprehensive assessment of the patient’s disease status, treatment response, and drug···【Read More】

  Update: 2026-02-05Source: Haiou HealthViews: 75

• Adverse Reactions of Golidocitinib

  Golidocitinib is a JAK/STAT signaling pathway inhibitor, mainly used for the treatment of relapsed or refractory T-cell lymphoma. Its common adverse r···【Read More】

  Update: 2026-02-05Source: Haiou HealthViews: 78

• Dosage and Administration of Golidocitinib

  The dosage and administration of golidocitinib must be strictly prescribed by a physician. Dosing is generally adjusted based on the patient’s disease···【Read More】

  Update: 2026-02-05Source: Haiou HealthViews: 78

• Golidocitinib Prescribing Information

  Golidocitinib is an oral targeted therapeutic agent indicated for the treatment of relapsed or refractory Peripheral T-Cell Lymphoma (PTCL). It inhibi···【Read More】

  Update: 2026-02-05Source: Haiou HealthViews: 81

• Zanubrutinib Use in Special Populations

  The use of zanubrutinib in special populations necessitates individualized adjustments based on each patient’s condition, with critical focus on safet···【Read More】

  Update: 2026-02-04Source: Haiou HealthViews: 83

• Zanubrutinib: Important Safety Information

  Zanubrutinib is a targeted therapeutic agent (a Bruton’s tyrosine kinase [BTK] inhibitor) used to treat certain types of lymphoma. It must be administ···【Read More】

  Update: 2026-02-04Source: Haiou HealthViews: 81